Dai, W.F.; Arciero, V.; Craig, E.; Fraser, B.; Arias, J.; Boehm, D.; Bosnic, N.; Caetano, P.; Chambers, C.; Jones, B.;
et al. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Curr. Oncol. 2021, 28, 4174-4183.
https://doi.org/10.3390/curroncol28050354
AMA Style
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B,
et al. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology. 2021; 28(5):4174-4183.
https://doi.org/10.3390/curroncol28050354
Chicago/Turabian Style
Dai, Wei Fang, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones,
and et al. 2021. "Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group" Current Oncology 28, no. 5: 4174-4183.
https://doi.org/10.3390/curroncol28050354
APA Style
Dai, W. F., Arciero, V., Craig, E., Fraser, B., Arias, J., Boehm, D., Bosnic, N., Caetano, P., Chambers, C., Jones, B., Lungu, E., Mitera, G., Potashnik, T., Reiman, A., Ritcher, T., Beca, J. M., Denburg, A., Mercer, R. E., Parmar, A.,
... on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group.
(2021). Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group. Current Oncology, 28(5), 4174-4183.
https://doi.org/10.3390/curroncol28050354
